Endometrioid Carcinoma

An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.

Also Known As:

Networked: 738 relevant articles (12 outcomes, 94 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Carcinoma (Carcinomatosis)
3.	Adenocarcinoma
4.	Neoplasm Metastasis (Metastasis)
5.	Hyperplasia

Experts

1.	Mylonas, Ioannis: 12 articles (01/2012 - 05/2005)
2.	Soslow, Robert A: 11 articles (07/2015 - 10/2002)
3.	Cho, Kathleen R: 10 articles (11/2015 - 04/2002)
4.	Broaddus, Russell R: 8 articles (01/2016 - 11/2005)
5.	Mhawech-Fauceglia, Paulette: 8 articles (08/2015 - 01/2010)
6.	Young, Robert H: 8 articles (04/2008 - 05/2002)
7.	Kikkawa, Fumitaka: 7 articles (01/2014 - 03/2003)
8.	Kajiyama, Hiroaki: 7 articles (01/2014 - 03/2003)
9.	Wu, Rong: 7 articles (01/2013 - 04/2002)
10.	Yaegashi, Nobuo: 7 articles (08/2012 - 06/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Endometrioid Carcinoma:

1.	Keratins (Keratin)IBA 09/01/2011 - "The low-molecular-weight cytokeratin (CK) protein CK19 has been shown to have diagnostic use and prognostic significance in some types of human malignancy, but little is known of its distribution in normal endometrial mucosa or in endometrial endometrioid adenocarcinoma. " 07/01/2000 - "Decidual tissue from first trimester normal pregnancies (NP; n = 15) and abortion (AB; n = 12), endometrial samples from premenopausal women (NE; n = 8), and endometrioid adenocarcinoma (EA; n = 8) were examined by immunohistochemistry using monoclonal antibody against large spectrum cytokeratin, and against the receptors CD3, CD8, CD56 and CD68, respectively. " 01/01/2011 - "Peritoneal keratin granuloma associated with endometrioid adenocarcinoma of the uterine corpus." 01/01/2006 - "Ovarian endometrioid carcinoma with diffuse pigmented peritoneal keratin granulomas: a case report and review of the literature." 11/01/1996 - "We concluded that cytokeratin immunostains can be helpful in distinguishing metastatic colonic adenocarcinoma from primary ovarian carcinomas, particularly endometrioid carcinomas. "
2.	Estrogens (Estrogen)FDA Link 10/01/2004 - "Endometrioid carcinomas (type I) are generally estrogen dependent, well-differentiated, superficially invasive, and have a good outcome. " 01/01/2012 - "This study investigated the role of miR-206 in estrogen receptor-α (ERα)-positive endometrial endometrioid adenocarcinoma (EEC). " 12/01/2008 - "The aim of this study was to analyze the expression of estrogen receptor (ER) beta in endometrioid carcinoma in comparison to non-neoplastic endometrium. " 06/01/2014 - "miR-22 inhibits proliferation and invasion in estrogen receptor α-positive endometrial endometrioid carcinomas cells." 01/01/2014 - "Overexpression of NPM1 may play a role in the effects of estrogen on the malignant progression of endometrioid adenocarcinoma via ERα signaling. "
3.	Messenger RNA (mRNA)IBA 01/01/2004 - "This study was designed to evaluate possible differences in the ER beta delta 6 and wtER beta messenger RNA (mRNA) level in the normal, hyperplastic endometrium, and endometrial endometrioid adenocarcinoma (G1, G2 morphological degree). " 08/01/2012 - "We measured by quantitative real-time polymerase chain reaction the mRNA expression of TAp63 and ΔNp63 in a series of 20 endometrioid adenocarcinomas paired with adjacent normal tissue. " 01/01/2010 - "Our results have identified, for the first time, unique patterns of Hp mRNA expression and protein localization in the stromal and glandular epithelial cells of endometrioid adenocarcinoma of the uterus. " 04/01/2009 - "In contrast, non-endometrioid adenocarcinomas had a higher frequency of p53 alterations (54%), PIK3CA mRNA overexpression (45%), and exon 20 PIK3CA mutations (21%). " 06/01/2008 - "The methylation rate of APC gene was significantly higher, the positive rates of APC mRNA and protein were significantly lower in endometrioid adenocarcinoma than in atypical hyperplastic endometrium and normal proliferative endometrium (65.0% vs. 33.3% and 23.3%, 33.3% vs. 63.3% and 73.3%, 30.0% vs. 50.0% and 66.7%,P<0.05). "
4.	Inhibins (Inhibin)IBA 11/01/2011 - "Thus, the inhibin-betaB subunit appears not to be a useful prognostic marker regarding endometrioid adenocarcinomas. " 11/01/2011 - "A series of 227 uterine endometrioid adenocarcinomas of a previous well-characterized cohort were re-evaluated for the expression of the inhibin-betaB subunit and correlated with several clinicopathological characteristics and the clinical outcome. " 11/01/2011 - "However, the prognostic significance and clinical implications of the inhibin-betaB subunit in uterine endometrioid adenocarcinomas is still not defined yet. " 08/01/2011 - "A series of 229 uterine endometrioid adenocarcinomas from a previously well-characterized cohort were re-evaluated for expression of the inhibin-βA subunit and correlated with several clinicopathological characteristics and clinical outcomes. " 08/01/2011 - "However, the prognostic significance and clinical implications of inhibin-βA subunits in uterine endometrioid adenocarcinomas have not been defined. "
5.	HormonesIBA 08/01/2013 - "Positive hormone-receptor expression (weak or strong staining for PR or ER, or both) was associated with significantly improved disease-specific survival in endometrioid carcinoma compared with negative hormone-receptor expression, independent of study site, age, stage, and grade (hazard ratio 0·33, 95% CI 0·21-0·51; p<0·0001). " 01/01/2015 - "The aim of this study was to compare the clinicopathological significance of miR-200a/miR-141 and miR-205 expression in endometrioid carcinomas (ECs) versus nonendometrioid carcinomas (NECs) and to assess their correlation with hormone receptor status. " 10/01/2009 - "P16 can serve as an additional diagnostic marker, used as part of an immunohistochemical panel, including p53 and hormone receptors, for distinction of uterine serous carcinomas from endometrioid carcinomas. " 10/01/2009 - "However, glandular variants of serous carcinoma can simulate Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) grade 2 endometrioid carcinomas, and some serous carcinomas lack p53 expression and retain hormone receptor expression, making classification difficult. " 10/01/2009 - "Uterine serous carcinomas typically have a characteristic morphology (papillary architecture, high-grade nuclei) and immunoprofile (diffuse/strong p53 expression, loss of hormone receptor expression) that distinguish them from most endometrial endometrioid carcinomas. "
6.	MucinsIBA 10/01/2003 - "In this study the authors evaluated the characteristics of mucin expression in the normal endocervical epithelium and mucinous and endometrioid adenocarcinomas of the uterine cervix. " 09/01/2004 - "Unlike FATWO, this variant of endometrioid carcinoma exhibits focal squamous differentiation, intraluminal mucin, mild to moderate nuclear atypia, and occasional mitosis. " 10/01/1982 - "The two features most helpful in differential diagnosis were the presence of areas of tumor with the typical confluent pattern of endometrioid carcinoma, and the presence of mucin at the apical borders of the tumor cells and/or within glandular lumina. " 06/01/2007 - "A number of histologic features can be used to distinguish the 2 entities, the most important ones being (1) the presence of areas with the usual pattern of endometrioid carcinoma, and (2) the presence of mucin at the apical borders of the tumor cells. " 04/01/1993 - "According to the morphological features, the results of mucin and immunohistochemical stainings, the histogenesis of cervical endometrioid adenocarcinoma and the differential diagnosis between cervical adenocarcinoma and endometrioid adenocarcinoma are discussed. "
7.	GhrelinIBA 05/01/2015 - "Ghrelin loss is helpful in differentiation between AEH and EIN from endometrioid adenocarcinoma, especially the well-differentiated grade. " 05/01/2015 - "Ghrelin loss was also related to poorly differentiated histologic grades of endometrioid carcinoma (p = 0.04). " 05/01/2015 - "Ghrelin loss or reduced expression was significantly related to endometrioid carcinoma, especially the well-differentiated type, compared with AEH and EIN (p = 0.000 and 0.006, respectively). " 05/01/2015 - "The relationship between Ghrelin expression and clinicopathologic features of endometrioid carcinoma was studied as well. " 05/01/2015 - "In the present study, immunohistochemical expression of Ghrelin was evaluated in 55 endometrioid carcinoma cases, as well as 26 endometrial hyperplasia cases. "
8.	Mifepristone (RU 486)FDA Link 05/01/2009 - ": Single-agent mifepristone used in the treatment of recurrent endometrioid adenocarcinoma or LGESS resulted in a stable disease rate of 25%. " 05/01/2009 - ": The objective of this study was to determine the efficacy of mifepristone (RU-486) in women with advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma (LGESS). " 05/01/2009 - "Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma." 05/01/2009 - ": Mifepristone (RU-486; 200 mg orally) was given daily to patients with progesterone receptor-positive advanced or recurrent endometrioid adenocarcinoma or LGESS. " 06/01/1990 - "Twelve cases of serous cystadenocarcinoma, 2 of mucinous cystadenocarcinoma, 2 of endometrioid carcinoma, one malignant Brenner tumor, and one yolk sac tumor were examined with respect to their response to estradiol (E2), [D-Ser(But)6]-LHRH (1-9) nonapeptide-etylamide (Buserelin), human menopausal gonadotropin (HMG), RU 38486 (RU), and pure FSH by subrenal capsule assay (SRCA). "
9.	Paclitaxel (Taxol)FDA LinkGeneric 01/01/1995 - "Extra-pelvic metastasis of endometrioid carcinoma; resistance to chemo-radiation therapy--response to paclitaxel treatment. " 01/01/2005 - "Adjuvant chemotherapy with paclitaxel and carboplatin in non-endometrioid carcinoma of the uterus." 03/01/2004 - "Complete remission of ovarian endometrioid adenocarcinoma associated with hyperamylasemia and liver metastasis treated by paclitaxel and carboplatin chemotherapy: a case report." 06/10/2014 - "Gene expression was assessed for 14 days post-treatment with carboplatin or carboplatin-paclitaxel in xenografts from two ovarian cancer models: platinum-sensitive serous adenocarcinoma-derived OV1002 and a mixed clear cell/endometrioid carcinoma-derived HOX424 with reduced sensitivity to platinum. " 07/01/2009 - "CD133(+) cells purified from endometrioid adenocarcinomas were resistant to cisplatin-induced and paclitaxel-induced cytotoxicity and expressed a peculiar gene signature consisting of high levels of matrix metalloproteases, interleukin-8, CD44, and CXCR4. "
10.	Carboplatin (JM8)FDA LinkGeneric 03/01/1987 - "The chemotherapeutic effects of CDDP, CBDCA and CHIP on human ovarian cancers heterotransplanted into nude mice (mucinous cystadenocarcinoma OVA-1, poorly differentiated adenocarcinoma OVA-2, endometrioid adenocarcinoma OVA-3, serous cystadenocarcinoma OVA-4, and three yolk sac tumors YST-1, YST-2, YST-3) were examined. " 01/01/2005 - "Adjuvant chemotherapy with paclitaxel and carboplatin in non-endometrioid carcinoma of the uterus." 03/01/2004 - "Complete remission of ovarian endometrioid adenocarcinoma associated with hyperamylasemia and liver metastasis treated by paclitaxel and carboplatin chemotherapy: a case report." 06/10/2014 - "Gene expression was assessed for 14 days post-treatment with carboplatin or carboplatin-paclitaxel in xenografts from two ovarian cancer models: platinum-sensitive serous adenocarcinoma-derived OV1002 and a mixed clear cell/endometrioid carcinoma-derived HOX424 with reduced sensitivity to platinum. "

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 01/01/2013 - "Patients with endometrioid adenocarcinoma, especially stage FIGO III, had favorable outcomes possibly meriting prospective evaluation of the addition of WAI following chemotherapy in selected patients. " 04/01/2010 - "The first patient with stage IVb moderately-differentiated endometrioid adenocarcinoma of the uterine corpus underwent initial operation and postoperative chemotherapy followed by maintenance chemotherapy. " 08/01/2004 - "To report a case of successful management of a FIGO stage III endometrioid carcinoma of the ovary diagnosed during pregnancy at 22 weeks of gestation and treated with initial chemotherapy while preserving the pregnancy. " 02/01/1986 - "Excluding endometrioid carcinoma, tissues from patients treated with chemotherapy contained less ER and PR than tissues from untreated patients. " 08/12/2002 - "To evaluate the therapeutic benefit of lymphadenectomy and adjuvant therapy, in particular chemotherapy, we retrospectively analysed survival rates and patterns of recurrence of endometrioid adenocarcinoma in 106 patients who underwent surgery including retroperitoneal lymphadenectomy. "
2.	Curettage 01/01/2015 - "In 2 cases, cytology of the endometrium was positive, and pathological analysis of curettage specimens indicated endometrioid adenocarcinoma. " 01/01/2014 - "Endometrioid adenocarcinoma was diagnosed by endometrial curettage. " 01/01/2014 - "219 patients were included who were operated on between 1996 and 2010 with a diagnosis of grade 1 endometrioid adenocarcinoma in probe curettage. " 07/01/2013 - "Curettage of the uterine endometrium revealed an endometrioid adenocarcinoma with squamous differentiation; i.e., an adenoacanthoma. " 02/01/2013 - "The material consists of cytologic smears including 20 cases of proliferative endometrium (PE), 20 cases of EGBD, and 20 cases of endometrioid adenocarcinoma grade1 (G1) for which histopathological diagnosis was obtained by endometrial curettage at the JA Suzuka General Hospital. "
3.	Combined Modality Therapy 10/01/2012 - "Compared to RT alone, combined modality therapy decreased recurrence and improved survival in patients with node-positive endometrioid adenocarcinoma of the uterus. "
4.	Lymph Node Excision (Lymph Node Dissection) 01/01/2012 - "Although a performed lymphadenectomy did not have any positive benefit in the survival of patients with uterine non-endometrioid carcinomas in this study, it might provide important prognostic information with a subsequent adjuvant treatment. " 01/01/2010 - "Therefore, this study evaluated whether lymphadenectomy has a prognostic impact in patients with endometrioid adenocarcinoma. " 01/01/2009 - "From our study, 33.6% of cases with a well differentiated endometrioid adenocarcinoma of the uterus were Stage Ic or more at the time of presentation; 12.2% were at least FIGO Stage Ic, eight patients (8.2%) were FIGO Stage IIa, seven patients (7.1%) were Stage IIb and six patients (6.1%) were Stage III. In these patients a full surgical staging operation with a pelvic lymphadenectomy was indicated according to FIGO recommendation. " 10/01/2015 - "To describe trends in the use of lymphadenectomy for endometrioid adenocarcinoma of the endometrium between 1998 and 2012. " 10/01/2015 - "Changing Trends in Lymphadenectomy for Endometrioid Adenocarcinoma of the Endometrium."
5.	Hysterectomy 07/01/2001 - "The present study of 100 endometrial samples showed focal desmoplastic stromal reaction with alpha-SM actin positive myofibroblasts in 30% of small samples and in 50% of hysterectomy specimens with endometrioid carcinoma. " 02/01/2015 - "A retrospective study was conducted to examine patients with grade 1 and 2 endometrioid adenocarcinoma diagnosed by preoperative endometrial biopsy who subsequently underwent hysterectomy-based surgical staging between 2000 and 2013. " 07/15/2014 - "67,397 women with stage I-II endometrioid adenocarcinoma after total hysterectomy diagnosed from 1988 to 2009 were identified in Surveillance, Epidemiology, and End Results (SEER) and linked SEER-Medicare databases. " 01/01/2014 - "Although description of similar lesions is available in the literature, the current lesion is unique as it is identified in a hysterectomy specimen in its entirety and its association with an endometrial endometrioid carcinoma. " 01/01/2014 - "The hysterectomy specimen showed a FIGO I stage 1a, endometrioid carcinoma. "